After Diane Shader Smith lost her daughter, Mallory, to a multidrug resistant infection, she turned her personal tragedy into a mission designed to inform people about antimicrobial resistance (AMR), and have the public coalesce around this expanding medical issue.
Patient-centered innovation amidst evolving regulations and policies is a key strategy.
Emily Ricotta, PhD, MSc outlines the importance of involving affected populations and refining data collection methods to improve early decision-making during epidemics
The Centers for Disease Control and Prevention (CDC) reports the rise in pediatric acute respiratory illnesses especially as there is a decrease in hygiene measures that were previously employed during the pandemic.
To close the discussion, experts on C. difficile infections discuss how they talk with patients about fecal microbiota transplantation.
Thumbi Ndung'u, BVM, PhD discussed the safety and partial virologic control observed in a Phase 2a trial using broadly neutralizing antibodies and vesatolimod in HIV treatment interruption.
In the second installment of our conversation with Jeremy Faust, MD, he addresses the uncertainty surrounding guidance and where to turn for information.
Here is a review of an opportunistic treatment approach to HCV infection in this patient population in a European study and some of the potential challenges in applying it in the United States.
Arbutus CEO Michael McElhaugh discussed trial results showing that a combination of imdusiran, an RNAi therapeutic, and pegylated interferon alfa-2α can achieve a functional cure in chronic hepatitis B patients.
Joseph Eron, MD, Daniel R. Kuritzkes, MD, and Monica Gandhi, MD, MPH, discuss the likelihood of other combination regimens for the treatment of multidrug-resistant HIV, including monoclonal antibodies.
At 7.1%, vitamin C deficiency in the US is rare. Unfortunately, identifying scurvy is complex, frustrating, and time-consuming for both patient and provider.
Sunil Parikh, MD, MPH, discusses the trial’s findings, noting no significant difference in malaria incidence (1.78 vs 1.84 cases per 100 person-weeks).
As the number of COVID-19 cases continues to rise, oral treatment options for at-home use are in demand to provide early intervention and reduce the progression to severe disease, hospitalization, and death.
Sasirekha Ramani, PhD on creating a broad-spectrum antiviral that could be effective in various clinical settings, especially given the emergence of new and more dominant strains.
Clinicians developed an algorithm and screening questionnaire for outpatient penicillin allergy evaluation, designed to stratify patients into high- and low-risk penicillin allergy groups. Here is the sample questionnaire to consider for use in clinics.
Katrine Wallace, PhD, and Eric John Burnett, MD, discuss the distinctions between them and strategies to understand better the information people are consuming.
This novel therapeutic option represents the first long-acting injectable approved for maintenance of HIV-1 suppression.
As someone who lives with the long-term effects of chikungunya, Camillo Mora PhD, sees the expanding habitat of mosquitos and is concerned more people will be exposed to vector-borne illnesses and deal with not only the acute phases of these viruses but also the possibility of long-term health effects they can present.
Social media platforms, public health agencies, and communities must join forces to stop the rapid spread of false information.
With evolving weather patterns, the natural habitat of ticks is expanding, and more people are becoming susceptible to them.
In this era of increasingly mobile and connected populations, it is possible for an infection to spread around the world in 24 to 48 hours.
At MAD-ID, Jose Alexander, MD, reports 98% susceptibility in ESBL E coli and 76% in K pneumoniae, underscoring the need for species-specific testing.
In a blinded phase 3 study, doravirine and islatravir was compared to antiretroviral therapy, BIC/FTC/TAF (Biktarvy), and it was shown that there was no between-group differences in mean change in CD4 T-cell or total lymphocyte count at week 48.
Georg Behrens, MD, PhD, highlights superior virological suppression and immune recovery with bictegravir-based therapy in therapy-naïve individuals with advanced HIV disease.
In the second part of an interview with Andrea Prinzi, PhD, MPH, SM(ASCP), she talks about how the March of Dimes played such a significant role against the disease and how the polio oral vaccine is a singular lesson that can be applied to medical science as a whole and the understanding of the need to adapt to changing circumstances.
Expert hepatologists discuss future developments in HCV that they are excited about and provide resources for new providers to get started on delivering HCV care.
Over 1 billion people are estimated to be affected by 20 conditions of neglected tropical diseases (NTDs), though they are often unheard of by many. Heather Saunders, MPH, RN, CIC, delves into 5 of these diseases and discusses efforts to stop their spread.
Sorana Segal-Maurer, MD, offers clinical insights on treating patients with HIV who have viral mutations, including M184V, highlighting guideline recommendations.